GlassScriptPhysician profile
John R Clough
NPI 1306843461
$3,086.97
in general payments reported to CMS, 2019-2025
23 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $585 · 2021: $179 · 2022: $351 · 2023: $549 · 2024: $519 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $820.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $399.61 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $358.22 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $334.26 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $259.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $230.30 | 2019-2022 | |
| Allergan, INC. | $147.03 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.19 | 2019-2023 | Xifaxan, Trulance |
| Amgen INC. | $61.94 | 2020-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $55.98 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.97 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $44.25 | 2022-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $43.31 | 2023-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $37.13 | 2023-2024 | Nuzyra |
| Eisai INC. | $36.32 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.95 | 2019-2020 | |
| Pfizer INC. | $23.03 | 2019-2020 | |
| Corcept Therapeutics | $18.75 | 2025 | Korlym |
| Amarin Pharma, INC. | $16.52 | 2021 | |
| Abbott Laboratories | $13.91 | 2023 | Freestyle Libre 2 |
| Genentech USA, INC. | $13.90 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.32 | 2023 | Jynarque |
| Zyla Life Sciences, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.